Humulin S (Soluble) (Insulin Human)

Humulin S is indicated for the management of blood glucose in patients with diabetes mellitus.

• Type 1 diabetes mellitus (insulin‑dependent) requiring rapid‑acting insulin to cover meals and correct post‑prandial glucose spikes.
• Type 2 diabetes mellitus in patients whose glycemic control is inadequate with oral hypoglycemic agents alone, necessitating supplemental rapid insulin.
• Management of hyperglycemia during pregnancy when the clinical benefit of tight glucose control outweighs potential fetal risks.
• In a basal‑bolus insulin regimen, providing the bolus (mealtime) component to rapidly lower glucose after carbohydrate intake.
• Hospital use for acute hyperglycemic emergencies such as diabetic ketoacidosis or severe hyperosmolar states, administered intravenously under monitoring.
• Combined with a long‑acting basal insulin to create a flexible, multiple‑daily‑injection schedule tailored to individual patient needs.

• Humulin S contains recombinant human insulin that binds to insulin receptors on muscle, adipose and hepatic cells. Receptor activation triggers autophosphorylation and downstream signaling through the PI3‑K/Akt pathway, promoting translocation of GLUT‑4 transporters to the cell surface and increasing glucose uptake. In the liver, insulin suppresses gluconeogenesis and glycogenolysis, reducing endogenous glucose production. The rapid onset of action mirrors the physiological insulin response to a meal.

Adverse reactions to Humulin S may vary in frequency and severity.

Common

• Mild hypoglycemia, especially if meals are delayed, carbohydrate intake is insufficient, or physical activity is increased.
• Injection site reactions such as redness, swelling, itching, or a small bruise may occur.
• Lipodystrophy, including lipohypertrophy or lipoatrophy at repeated injection sites, can affect insulin absorption.
• Transient weight gain due to fluid retention is occasionally observed, particularly with high insulin doses.
• Nausea or mild gastrointestinal discomfort, often transient, may be reported after injection.

Serious

• Severe hypoglycemia with neuroglycopenic symptoms such as confusion, seizures, loss of consciousness, or coma requires immediate treatment.
• Allergic reactions ranging from urticaria and localized swelling to systemic anaphylaxis can occur and need prompt medical attention.
• Persistent edema or worsening heart failure may develop in patients with underlying cardiac disease, especially when high insulin doses are used.

When prescribing or using Humulin S, several precautions should be considered to ensure safe and effective therapy.

• Assess renal and hepatic function, as impairment can prolong insulin action and increase hypoglycemia risk.
• Monitor blood glucose closely during dose adjustments, illness, or changes in diet and physical activity.
• Use caution in pregnant or breastfeeding women; benefits must outweigh potential risks to the fetus or infant.
• Avoid using Humulin S in patients with known hypersensitivity to human insulin or any excipients.
• Educate patients on proper injection technique and site rotation to prevent lipodystrophy.
• Consider cardiovascular status, as rapid‑acting insulin may exacerbate fluid retention in heart failure patients.

Humulin S may interact with other medications, affecting glucose control or increasing the risk of adverse events.

Avoid

• Concurrent use of other rapid‑acting insulins or insulin secretagogues (e.g., sulfonylureas, meglitinides) may cause profound hypoglycemia.
• Beta‑blockers can mask hypoglycemia symptoms and should be avoided when possible.
• High‑dose corticosteroids may antagonize insulin action, requiring dose adjustments.

Use with caution

• Concurrent thiazide diuretics can increase blood glucose levels, necessitating closer monitoring.
• ACE inhibitors and ARBs may enhance insulin sensitivity, potentially requiring dose reduction.
• Alcohol intake can potentiate insulin’s hypoglycemic effect; patients should be advised to limit consumption.